DrJennifer Miller

A Phase 3, Multicenter, Open-Label Extension Study to Assess the Safety and Efficacy of ARD-101 in Patients with Prader-Willi Syndrome

A Phase 3, Randomized, Double-blind, Placebo-controlled Study of ARD-101 for the Treatment of Hyperphagia in Patients with Prader-Willi Syndrome

RM-493-043 - A Phase 2, Single-center, Open-label Study of Setmelanotide in Patients with Prader-Willi Syndrome

Open-Label Extension Study of Setmelanotide in Patients with a Rare Genetic, Syndromic or Acquired Disease of the MC4R Pathway

A Phase 3, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Setmelanotide in Patients with Acquired Hypothalamic Obesity

An Open-Label Study of DCCR (Diazoxide Choline) Extended-Release Tablets in Patients with Prader-Willi Syndrome

A 2-Stage (Open-Label Run-in followed by Randomized Withdrawal), Double-Blind, Placebo-Controlled, Phase 2 Study of Setmelanotide in Patients with Specific Gene Defects in the Melanocortin-4 Receptor Pathway

A Phase 2a Evaluation of Psilocybin (TRP-8802) Administration in Concert with Psychotherapy to Decrease Hyperphagia in Patients with Overeating Disorders

A Phase 2, Open-Label 20-Week Study to Evaluate the Safety and Efficacy of Setmelanotide in Subjects with Hypothalamic Obesity

Research Supportive Service Agreement

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients with Prader-Willi Syndrome, Followed by an Open Label Extension

An Open-Label, Long-Term Safety Study to Evaluate the Safety and Tolerability of Pitolisant in Pediatric Patients with Prader-Willi Syndrome (PWS) who Participated in Study HBS-101-CL-003

Long Term Extension Trial of setmelanotide (RM-493) for patients who have completed a trial of setmelanotide for the treatment of obesity associated with genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway

PATH for PWS - PATH Study Investigator

Phase 3, Randomized, Double-Blind, Placebo-Controlled, 8-week Clinical Study to Assess the Efficacy, Safety, and Tolerability, of Intranasal Carbetocin (LV-101) in Prader-Willi Syndrome (PWS) with Long Term Follow-Up: CARE-PWS

An Open-Label, Long-Term Safety Evaluation of Diazoxide Choline Controlled-Release Tablet in Patients with Prader-Willi Syndrome

Setmelanotide (RM-493) Phase 2 Treatment Trial in Patients with rare genetic disorders of obesity

A Randomized, Double-Blind, Placebo-Controlled Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients with Prader-Willi Syndrome

A Phase 2 Study to Evaluate Efficacy, Safety, and Pharmacokinetics of GLWL-01 in the Treatment of Patients with Prader-Willi syndrome (PWS)

Evaluating Factors that may affect the Efficacy of Intranasal Oxytocin Treatment in PWS

Phase 2 Study: Intranasal Oxytocin for Treatment of Infants and Children with Prader-Willi Syndrome in Nutritional Phase 1a

Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers

Prader-Willi Syndrome Research Fund

A Phase 2 Randomized Double-Blind Placebo-controlled Pilot Study to Assess the Effects of RM-493 a Melanocortin 4 Receptor (MC4R) Agonist in Obese Subjects with Prader-Willi Syndrome (PWS) on Safety Weight Reduction and Food-Related Behaviors

A Phase 2, Randomized, Double-Blind Placebo-controlled Pilot Study to Assess the Effects of RM-493, a Melanocortin 4 Receptor Agonist in Obese Subjects with Prader-Willi Syndrome on Safety, Weight Reduction, and Food-Related Behaviors